HPS6 Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the NCI-H1975 human lung adenocarcinoma cell line. This product features targeted disruption of the HPS6 gene, which encodes a subunit of the BLOC-2 complex. The polyclonal population maintains a heterogeneous knockout profile, providing a robust model to study gene function without clonal selection biases.
The parental NCI-H1975 cell line is a well-established model of non-small cell lung cancer adenocarcinoma, harboring an EGFR exon 20 insertion mutation and a TP53 mutation. These genetic alterations drive oncogenic signaling and tumor progression, making the cell line highly relevant for investigating EGFR-targeted therapies and mechanisms of drug resistance. The epithelial origin and clinical mutational background of NCI-H1975 offer a translationally pertinent system for lung cancer research.
HPS6 is a core component of the biogenesis of lysosome-related organelles complex 2 (BLOC-2), which also includes HPS3 and HPS5. This complex acts downstream of the transcription factors MITF and TFEB to regulate the trafficking of cargo proteins such as TYRP1 to melanosomes and serotonin and ADP to platelet dense granules. BLOC-2 functionally interacts with the AP-3 adaptor complex and the small GTPase Rab32, coordinating vesicular transport events essential for lysosome-related organelle biogenesis. Disruption of HPS6 therefore compromises these trafficking pathways, leading to defects in organelle maturation and cargo delivery.
In the context of NCI-H1975 lung adenocarcinoma cells, HPS6 knockout provides a powerful tool to dissect the interplay between lysosome-related organelle function and cancer biology. EGFR signaling and TP53 deficiency are known to influence endolysosomal trafficking, autophagy, and secretion, processes that may be modulated by BLOC-2 activity. Loss of HPS6 can help elucidate how vesicular trafficking perturbations affect tumor cell proliferation, invasion, and response to tyrosine kinase inhibitors, offering insights into novel therapeutic vulnerabilities.
Researchers can employ these polyclonal knockout cells in a variety of functional assays, including Western blotting to verify HPS6 protein loss and downstream target changes, immunofluorescence to examine TYRP1 localization and lysosome morphology, RT-qPCR for transcription analysis, and electron microscopy for ultrastructural characterization. Additionally, migration and invasion assays, as well as drug sensitivity panels, enable the assessment of HPS6-dependent phenotypes in tumor aggressiveness and therapeutic resistance. For further details or to discuss specific experimental needs, please contact Ascent Research.
